ALK’s partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan

Pharmaceutical Investing

ALK (OMX:AKBLF) announced that its partner for Japan, Torii, has gained approval from the Japanese Ministry of Health, Labour and Welfare, to expand the use of ALK’s house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients. As quoted in the press release: Henrik Jacobi, ALK’s Executive Vice President, Research …

As quoted in the press release:

Henrik Jacobi, ALK’s Executive Vice President, Research & Development, said: “Since its original launch, MITICURE™ has steadily been finding favour with prescribers, and latest market reports from Japan show that the uptake has now reached encouraging levels and that our partner Torii has clear market leadership. The addition of a paediatric indication extends this innovative treatment option to an important new patient population, children, for whom the long-term effects of respiratory allergy can be particularly damaging.”

Click here to read the full press release.

health immunotherapy japan patient patients treatment option Pharmaceutical Investing